GLOW Peptide: Three constituents, three recovery pathways, one published literature.

What Is GLOW Peptide?

GLOW peptide is a three-constituent research blend combining GHK-Cu (glycyl-L-histidyl-L-lysine copper complex), BPC-157 (body protection compound, 15 amino acids), and TB-500 (the synthetic active heptapeptide of thymosin beta-4). Each constituent has an independent preclinical research profile. No randomized controlled trial has studied the combined formulation as a single compound — all evidence cited on this site pertains to the individual peptides.

GHK-Cu is a tripeptide found naturally in human plasma, with levels declining from approximately 200 ng/mL at age 20 to roughly 80 ng/mL by age 60 ^[2]. BPC-157 is a 15-amino-acid stable peptide derived from a partial sequence of human gastric juice protein, studied for tissue-repair and cytoprotective effects across rodent models ^[8]. TB-500 is the active heptapeptide (Ac-LKKTETQ) corresponding to amino acids 17-23 of full-length thymosin beta-4, responsible for actin sequestration and angiogenic signaling ^[20].

The GLOW 70 designation refers to a 70 mg total lyophilized peptide formulation distributed across the three constituents in a single vial.

For detailed constituent mechanisms, see GHK-Cu mechanism of action, BPC-157 tissue repair, and TB-500 recovery research.

What Is GLOW Peptide Used For?

In preclinical research, the GLOW blend's constituents have been studied for three broad tissue categories:

Extracellular matrix and skin repair. GHK-Cu stimulated collagen synthesis in cultured human fibroblasts beginning at 10⁻¹² to 10⁻⁹ M — independent of cell proliferation, indicating direct gene-level stimulation ^[1]. In human clinical trials, 12-week topical application improved skin density, firmness, and wrinkle depth in 41-to-71-participant studies, and procollagen synthesis was achieved in 70% of treated volunteers ^[23].

Tendon, ligament, and muscle recovery. BPC-157 increased growth hormone receptor (GHR) expression up to sevenfold in rat tendon fibroblasts ^[9] and produced full functional recovery in surgically detached quadriceps muscle in rats by days 21-28 — untreated controls showed permanent disability ^[10]. TB-500 acts as a chemoattractant for myoblasts at injury sites, driving muscle-fiber regeneration in rodent models ^[16].

Angiogenesis and vascular ingrowth. Both BPC-157 and TB-500 activate VEGFR2-mediated and PI3K/Akt/eNOS signaling cascades to form new capillaries in healing tissue ^[17]. Thymosin beta-4, the parent protein of TB-500's active fragment, reached Phase II clinical trials for wound repair, corneal healing, and cardiac recovery ^[17].

The recovery and tissue-repair angle is where the constituent literature is deepest. GLOW peptide benefits covers the full evidence map by tissue type.

What Does the GLOW Peptide Do?

The GLOW blend targets three complementary mechanisms in sequence. GHK-Cu remodels the extracellular matrix — stimulating collagen I/III and glycosaminoglycan synthesis while suppressing pro-fibrotic TGF-beta1/Smad2/3 signaling ^[4]. BPC-157 addresses tissue-injury repair by upregulating growth hormone receptor expression in fibroblasts and activating the VEGFR2-Akt-eNOS angiogenic axis ^[9]. TB-500 drives cell migration and vascular ingrowth via G-actin sequestration and VEGF upregulation in endothelial progenitor cells ^[15].

Together, the three peptides address what single-constituent protocols typically address individually: matrix-building, injury repair, and vascular recovery. See the GLOW peptide side effects section on /research for tolerability data across the preclinical literature.

What Is the GLOW Blend Peptide Stack?

The GLOW blend peptide stack is a three-constituent combination designed to address complementary repair pathways in a single formulation. The mechanistic rationale: GHK-Cu provides copper-mediated collagen cross-linking and extracellular matrix organization; BPC-157 provides injury-specific repair via GHR-JAK-STAT signaling in fibroblasts and nitric oxide modulation; TB-500 provides myoblast recruitment and angiogenesis via actin sequestration and VEGF upregulation ^[17].

Each pairwise combination has its own research rationale. GHK-Cu plus BPC-157 addresses matrix rebuilding and vascular supply simultaneously. BPC-157 plus TB-500 — the most widely referenced pair in the peptide therapy literature — has been noted in a 2026 American Journal of Sports Medicine review study for tissue repair and recovery contexts [finding from common_stacks_research]. The three-peptide stack layers all three mechanisms.

No combination trial has been published for the full GLOW blend. The stack rationale is mechanistic extrapolation from individual-constituent evidence. See GLOW peptide dosage for the studied dose ranges of each constituent.

GLOW Peptide Ingredients: The Three-Peptide Blend

GHK-Cu — Glycyl-L-histidyl-L-lysine copper complex. Molecular weight 340.4 Da. A naturally occurring tripeptide complexed with a copper(II) ion; the copper is delivered safely to lysyl oxidase and other copper-dependent enzymes for collagen cross-linking. Plasma levels are endogenous but decline with age ^[22].

BPC-157 — Body Protection Compound 157. The sequence GEPPPGKPADDAGLV, 15 amino acids, molecular weight 1419.5 Da. Stable in human gastric juice for over 24 hours; active at microgram-to-nanogram dose ranges in rodent studies ^[8]. IV half-life 15.2 min in rats, 5.27 min in dogs; IM bioavailability 14-51% across species ^[14].

TB-500 — Thymosin beta-4 active fragment, the heptapeptide Ac-LKKTETQ (amino acids 17-23 of the full 43-amino-acid thymosin beta-4 protein). Molecular weight 882.0 Da. Terminal half-life 0.5-2.08 hours IV in Phase I human trial ^[18]. Detectable in equine plasma at 0.02 ng/mL sensitivity ^[20].

What Is the GLOW 70 Protocol? The GLOW 70 designation refers to a 70 mg total peptide formulation across the three constituents in a single lyophilized vial. Reconstitution typically uses 3 mL bacteriostatic water, yielding approximately 23 mg/mL total peptide concentration.